XPO1 and cancer: Data was available for 11,768 individuals in the pan-Cancer cohort, and these showed that high levels of ncr1 expression were associated with an enhanced median survival of 2910 days versus 2089 days, P = 0.017 in individuals with higher levels of XPO1.